• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    4/19/22 2:37:39 PM ET
    $AFIB
    $AGRX
    $AXSM
    $AYTU
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFIB alert in real time by email

     

    Gainers

    • Checkmate Pharmaceuticals (NASDAQ:CMPI) stock increased by 331.9% to $10.41 during Tuesday's regular session. Trading volume for Checkmate Pharmaceuticals's stock is 3.4 million as of 13:30 EST. This is 25265.9% of its average full-day volume over the last 100 days. The company's market cap stands at $225.1 million.
    • Sharps Technology (NASDAQ:STSS) shares moved upwards by 45.06% to $2.51. Trading volume for this security as of 13:30 EST is 101.5 million, which is 4236.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $23.0 million.
    • Axsome Therapeutics (NASDAQ:AXSM) stock rose 23.57% to $40.41. Trading volume for Axsome Therapeutics's stock is 9.4 million as of 13:30 EST. This is 1278.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.5 billion.
    • Acutus Medical (NASDAQ:AFIB) stock increased by 15.71% to $0.99. Trading volume for this security as of 13:30 EST is 568.2K, which is 110.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $27.8 million.
    • Olema Pharmaceuticals (NASDAQ:OLMA) stock moved upwards by 14.95% to $3.37. Olema Pharmaceuticals's stock is trading at a volume of 735.0K shares as of 13:30 EST. This is 179.4% of its average full-day volume over the last 100 days. The company's market cap stands at $135.9 million.
    • Evoke Pharma (NASDAQ:EVOK) stock moved upwards by 14.86% to $0.42. Evoke Pharma's stock is trading at a volume of 205.3K shares as of 13:30 EST. This is 190.2% of its average full-day volume over the last 100 days. The company's market cap stands at $13.9 million.

     

    Losers

    • Lyra Therapeutics (NASDAQ:LYRA) shares fell 15.0% to $5.89 during Tuesday's regular session. The current volume of 249.3K shares is 128.0% of Lyra Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $187.4 million.
    • Sunshine Biopharma (NASDAQ:SBFM) stock fell 14.17% to $2.97. Trading volume for this security as of 13:30 EST is 2.2 million, which is 21.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.1 million.
    • Cassava Sciences (NASDAQ:SAVA) stock fell 14.07% to $21.75. As of 13:30 EST, this security is trading at a volume of 6.4 million shares, making up 399.7% of its average full-day volume over the last 100 days. The company's market cap stands at $870.4 million.
    • Dentsply Sirona (NASDAQ:XRAY) stock fell 11.82% to $42.97. Trading volume for this security as of 13:30 EST is 10.5 million, which is 518.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.2 billion.
    • Aytu BioPharma (NASDAQ:AYTU) shares fell 10.89% to $0.81. Aytu BioPharma's stock is trading at a volume of 34.8 million shares as of 13:30 EST. This is 16981.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $27.1 million.
    • Agile Therapeutics (NASDAQ:AGRX) stock fell 10.58% to $0.16. As of 13:30 EST, this security is trading at a volume of 13.0 million shares, making up 197.2% of its average full-day volume over the last 100 days. The company's market cap stands at $22.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AFIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB
    $AGRX
    $AXSM
    $AYTU

    CompanyDatePrice TargetRatingAnalyst
    Olema Pharmaceuticals Inc.
    $OLMA
    3/19/2026Buy
    Jefferies
    Axsome Therapeutics Inc.
    $AXSM
    2/24/2026$230.00Outperform
    Wolfe Research
    DENTSPLY SIRONA Inc.
    $XRAY
    2/19/2026$17.00Neutral → Buy
    BofA Securities
    Olema Pharmaceuticals Inc.
    $OLMA
    2/11/2026$48.00Buy
    Stifel
    Axsome Therapeutics Inc.
    $AXSM
    1/8/2026$204.00Overweight → Equal-Weight
    Morgan Stanley
    Olema Pharmaceuticals Inc.
    $OLMA
    1/7/2026$40.00Overweight
    Piper Sandler
    DENTSPLY SIRONA Inc.
    $XRAY
    12/9/2025$12.00Underweight
    Barclays
    DENTSPLY SIRONA Inc.
    $XRAY
    11/7/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $AFIB
    $AGRX
    $AXSM
    $AYTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Olema Pharmaceuticals

    Jefferies resumed coverage of Olema Pharmaceuticals with a rating of Buy

    3/19/26 8:27:01 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Axsome Therapeutics with a new price target

    Wolfe Research initiated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $230.00

    2/24/26 7:45:48 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dentsply Sirona upgraded by BofA Securities with a new price target

    BofA Securities upgraded Dentsply Sirona from Neutral to Buy and set a new price target of $17.00

    2/19/26 7:47:02 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $AFIB
    $AGRX
    $AXSM
    $AYTU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

    SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present two preclinical posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California. Poster Presentation Details Title: Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alphaPoster/Abstract: 2950Session: Experimental and Molecular Therapeutics: Cellular

    3/17/26 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancerAdvanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients with frontline ER+/HER2- metastatic breast cancer Initiated the Phase 1b/2 study of palazestrant in combination with Pfizer's novel CDK4 inhibitor, atirmociclib, in patients with ER+/HER2- metastatic breast cancerContinued enrollment in the Phase 1 clinical study of OP-3136 in breast cancer and other solid tumors, with initial clinical data expected in Q2 2026Generated $218.5 million in gross proce

    3/16/26 7:00:00 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

    New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under "FLNA" effective March 11, 2026 AUSTIN, Texas, March 10, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. ("Filana Therapeutics", or the "Company"). The new name and corporate brand reflect the Company's strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC

    3/10/26 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $AGRX
    $AXSM
    $AYTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President, CEO & Member of BOD Scavilla Daniel T

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/12/26 5:44:35 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by EVP, Chief Commercial Officer Denti Aldo Mariano Roberto

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/12/26 5:41:09 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by VP, Chief Accounting Officer Czerney Kevin

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/12/26 5:38:47 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $AFIB
    $AGRX
    $AXSM
    $AYTU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

    Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    8/19/22 12:36:14 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for GIMOTI

    Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

    1/15/21 5:10:35 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $AGRX
    $AXSM
    $AYTU
    SEC Filings

    View All

    SEC Form 8-K filed by Lyra Therapeutics Inc.

    8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

    3/16/26 4:30:39 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    3/16/26 4:03:51 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    3/16/26 12:43:51 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $AGRX
    $AXSM
    $AYTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T bought $186,675 worth of shares (15,000 units at $12.45) (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/9/26 4:20:49 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Forbes James D bought $62,400 worth of shares (5,000 units at $12.48), increasing direct ownership by 100% to 10,000 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/9/26 4:19:42 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Lucier Gregory T bought $707,379 worth of shares (50,000 units at $14.15) (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/3/26 7:12:19 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $AFIB
    $AGRX
    $AXSM
    $AYTU
    Leadership Updates

    Live Leadership Updates

    View All

    Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors

    CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) --  DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the "Board"), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 years of experience helping companies develop strategies to drive profitable growth and long-term value creation. Mr. Forbes is widely recognized for advising healthcare companies on complex strategic transactions and capital markets engagements. He most recently served as Vice Chairman of Investment Banking at Morgan Stanley, and he previously held senior execu

    2/24/26 4:30:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Donald Zurbay to Board of Directors

    CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the "Board"), effective January 10, 2026. He will be joining the Board's Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership

    1/13/26 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization

    CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28. The appointment supports Dentsply Sirona's continued focus on strengthening commercial execution, deepening customer relationships and accelerating growth across the Americas. Mr. Bezjak is a seasoned commercial executive with more than 20 years of experience leading large-scale, multi-billion-dollar organizations in the medical device

    1/12/26 9:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $AFIB
    $AGRX
    $AXSM
    $AYTU
    Financials

    Live finance-specific insights

    View All

    Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook

    News Summary Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of taxQ4 2025 adjusted EPS of $0.27FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50(1)Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistryInitiated new capital allocation strategy by eliminating the dividend

    2/26/26 4:01:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively,representing 65% and 66% year-over-year growth AUVELITY® 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively,representing 68% and 74% year-over-year growth SUNOSI® 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively,representing 40% and 32% year-over-year growth SYMBRAVO® 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively sNDA for AXS-05 for the treatment of Alzheimer's disease agitation granted Priority Review with PDUFAtarget action date of April 30, 2026 Acquired AXS-17, a novel

    2/23/26 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dentsply Sirona to Host Fourth Quarter and Full Year Conference Call on February 26

    CHARLOTTE, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, February 26, 2026, at 4:30 p.m. EST to review its fourth quarter and full year 2025 financial results. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at http

    2/5/26 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $AFIB
    $AGRX
    $AXSM
    $AYTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care